Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Retinal Disorder Treatment Market Size & Share 2026-2035
Report ID: GMI10121
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Retinal Disorder Treatment Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Retinal Disorder Treatment Market Size
The retinal disorder treatment market was valued at USD 18.8 billion in 2025, is expected to reach USD 20.1 billion in 2026, is projected to expand at a 6.8% CAGR (2026-2035), and is forecast to reach USD 36.4 billion by 2035.
Retinal Disorder Treatment Market Key Takeaways
Market Leader: Regeneron Pharmaceuticals led with over 25% market share in 2025.
Leading Players: Top 5 players in this market include Regeneron Pharmaceuticals, Roche/Genentech, Bayer AG, Novartis AG, Apellis Pharmaceuticals, which collectively held a market share of 73% in 2025.
The market covers demand-side manufacturer revenue from biologics, complement inhibitors, gene and cell therapies, sustained-release systems, conventional medicines, laser therapy, and vitreoretinal surgery used across retinal diseases.
The retinal disorder treatment market is being reshaped by the interaction of a growing treated population and a changing revenue mix. Diabetes and population aging enlarge the clinical pool for diabetic retinal disease and age-related macular degeneration, while biosimilar adoption changes anti-VEGF pricing and newer treatment modalities create opportunities in previously underserved indications.
GMI Analyst View
Our analysis of company performance disclosures and industry expert discussions indicates that the global retinal disorder treatment market reached USD 18.0 billion in revenue during 2024, reflecting accelerating Vabysmo (faricimab) market penetration, the initial commercial contribution of complement inhibitors for geographic atrophy, and sustained EYLEA HD conversion activity ahead of the base year. This trajectory provides meaningful validation of the base-year market sizing recorded in our model.
Retinal Disorder Treatment Market Trends, Growth Drivers & GMI Forecast Outlook
Forecast performance depends on whether expanding diagnosis and treatment capacity can convert a larger retinal disease population into sustained care. Biosimilars broaden access but reduce revenue per treatment episode, while longer-acting therapies and gene therapy programs could improve persistence and introduce new sources of value later in the forecast period.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Diabetic retinal care increasingly depends on screening reach, referral pathways, and the capacity of retinal practices to sustain repeat-treatment regimens. As diagnosis becomes more systematic in underpenetrated health systems, the principal commercial effect is expected to be greater conversion of prevalent diabetic retinal disease into active treatment rather than a uniform shift toward premium brands.
Population aging supports both established anti-VEGF demand and the developing geographic atrophy treatment category. In parallel, biosimilar approvals alter procurement choices and lower barriers to initiation, whereas sustained-release and gene therapy programs could reduce the practical burden created by repeated intravitreal procedures. The forecast therefore assumes that treatment volumes broaden before innovation makes a larger contribution to revenue mix.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Treatment affordability has consequences beyond product substitution. Administrative controls and step therapy can delay initiation, shift use toward lower-cost alternatives, and make reimbursement predictability a central determinant of physician adoption for recently launched products. This is especially consequential for therapies requiring continuing administration or complex site-of-care processes.
Non-adherence constrains the market's ability to translate clinical prevalence into realized treatment demand. Lower-burden dosing formats, implantable delivery systems, and one-time therapeutic approaches may improve retention, but their effect depends on reimbursement, provider readiness, and clinical confidence. These constraints keep revenue growth below the level implied by epidemiology alone.
GMI Analyst View
We see a two-stage market transition. Established anti-VEGF franchises remain essential to near-term demand, but their economics are being reset by biosimilars and payer management. Later, sustained-release delivery and gene therapy could change the relationship between treatment persistence, site of care, and value capture if execution hurdles are overcome.
Retinal Disorder Treatment Market Segment Analysis
By Treatment Type
Advanced biologics accounted for 65% of retinal disorder treatment market revenue in 2025 and are projected to represent 56% by 2035. Anti-VEGF therapies retain the broadest installed treatment base in wet AMD and diabetic retinal disease, but biosimilar competition and the emergence of complementary therapeutic categories reduce their relative weight without eliminating their central role.
Gene & cell therapy is projected to generate USD 4.73 billion by 2035 and advance at a 28.8% CAGR (2026-2035). The segment's commercial trajectory is tied to regulatory timing, specialist-center capacity, manufacturing reliability, and payer willingness to support therapies with high upfront cost and potentially durable clinical benefit.
Implantable drug delivery systems generated USD 940 million in 2025 and are forecast to grow at a 12.0% CAGR (2026-2035). Their strategic value lies in addressing the repeat-injection burden that contributes to discontinuation, although procedure economics and physician training remain important adoption constraints.
Conventional pharmaceutical treatments represented 15% of revenue in 2025 and are expected to account for 13% by 2035. Cost-sensitive demand and the continued role of corticosteroids and off-label options preserve a durable volume base, particularly where reimbursement restricts use of premium biologics.
Laser therapy held 7% of revenue in 2025 and is projected to reach USD 1.82 billion by 2035. Pharmacological treatments have displaced standalone laser use in several indications, but laser remains clinically relevant for selected disease presentations and settings with constrained biologic access.
Surgical procedures generated USD 1.13 billion in 2025 and are expected to account for 5% of revenue by 2035. This category is driven primarily by procedural need in retinal detachment and vitreoretinal care, making its outlook more closely linked to care capacity and intervention volumes than to drug innovation.
By Disease Type
Wet AMD accounted for 47% of retinal disorder treatment market revenue in 2025 and is expected to represent 38% by 2035. It remains the largest revenue pool because of the established anti-VEGF treatment base, although longer dosing intervals, biosimilar use, and growth in newer disease categories dilute its overall share.
Dry AMD / Geographic Atrophy is projected to reach USD 5.46 billion by 2035 and grow at a 13.7% CAGR (2026-2035). Complement inhibition has created a pharmacological market where disease management historically lacked one, but treatment uptake will depend on diagnostic practices, clinical confidence, and formulary access.
Diabetic retinopathy generated USD 3.20 billion in 2025 and is expected to expand at a 7.4% CAGR (2026-2035). Screening expansion and improved treatment access determine how effectively the growing diabetic population is converted into managed disease, while new modalities could broaden intervention options beyond existing injection-based care.
Diabetic macular edema is projected to generate USD 5.46 billion by 2035 and represented 15% of revenue in 2025. Intensive treatment requirements make adherence and follow-up central to revenue realization, creating a strong rationale for longer-acting products and delivery systems that reduce visit burden.
Retinal vein occlusion is forecast to reach USD 2.55 billion by 2035 and accounted for 7% of revenue in 2025. The indication benefits from wider therapeutic choice within anti-VEGF care, but its commercial development remains shaped by reimbursement conditions and specialist treatment capacity.
Inherited retinal dystrophies are projected to generate USD 1.46 billion by 2035 and advance at a 14.4% CAGR (2026-2035). The category is clinically heterogeneous, so commercial progress will depend on the ability of gene therapy developers to match genetically defined populations with viable testing, referral, and payment pathways.
Retinal detachment represented 3% of revenue in 2025 and is expected to account for 2% by 2035. Surgical intervention remains indispensable, but the segment's relative position is moderated by faster-growing pharmaceutical and biologic categories.
Other retinal disorders held 1% of revenue in 2025 and are projected to generate USD 364 million by 2035. This residual category remains relevant where smaller indications benefit from specialist treatment expansion, even though individual disease populations do not approach the scale of AMD or diabetic retinal disease.
By End-User
Hospitals represented 60% of revenue in 2025 and are expected to account for 55% by 2035. They remain essential for complex procedures, multidisciplinary monitoring, and advanced therapy administration, while routine injection care increasingly migrates to dedicated outpatient settings.
Specialty clinics are projected to generate USD 12.01 billion by 2035 and grow at a 7.8% CAGR (2026-2035). Their expansion reflects the operational advantages of retina-focused practices, including imaging capabilities, repeat-treatment workflows, and patient convenience.
Homecare settings accounted for 7% of revenue in 2025 and are forecast to advance at a 9.6% CAGR (2026-2035). Their development depends on therapies that can be safely administered or monitored outside traditional facilities, along with the service models needed to manage patient adherence.
Other end users are projected to generate USD 1.09 billion by 2035 and represented 3% of revenue in 2025. Institutional and long-term-care environments provide incremental treatment access where mobility, monitoring, and continuity-of-care requirements shape the route to therapy.
By Distribution Channel
Hospital pharmacy accounted for 68% of revenue in 2025 and is expected to represent 62% by 2035. Its role reflects buy-and-bill practices and facility-based administration, although a broader mix of outpatient and home-oriented care reduces its relative share over time.
Retail pharmacy is projected to generate USD 9.1 billion by 2035 and expand at an 8.2% CAGR (2026-2035). Growth depends on whether pipeline products move retinal treatment toward more conventional dispensing models and whether payers support those routes of access.
Online pharmacy represented 10% of revenue in 2025 and is forecast to advance at a 9.6% CAGR (2026-2035). Digitally enabled fulfillment can support specialty distribution and home delivery, but adoption remains dependent on the suitability of products for remote dispensing and patient management.
GMI Analyst View
We believe the most consequential segment shift is not simply from one drug to another. It is the movement from repeat-treatment franchises toward care models that seek to lower treatment burden. The winners will be those that combine differentiated clinical performance with credible reimbursement, administration, and follow-up pathways.
Retinal Disorder Treatment Market Regional Analysis
North America Retinal Disorder Treatment Market Analysis
North America accounted for 55.0% of retinal disorder treatment market revenue in 2025 and is projected to represent 48.0% by 2035. Mature biologic prescribing, specialist infrastructure, and earlier access to innovative therapies support the region's scale, while faster growth elsewhere reduces its share of the global market.
U.S.
The U.S. retinal disorder treatment market generated USD 9.5 billion in 2025 and is projected to reach USD 15.6 billion by 2035. The market combines extensive retinal specialist capacity with intense biosimilar competition, active payer management, and early commercialization opportunities for complement inhibitors and gene therapies.
Canada
Canada accounted for 4.5% of revenue in 2025 and is forecast to grow at an 8.4% CAGR (2026-2035). Provincial coverage decisions, newer formulary inclusions, and biosimilar adoption support expansion from a comparatively smaller base.
Europe Retinal Disorder Treatment Market Analysis
Europe is projected to generate USD 7.64 billion by 2035 and expand at a 6.3% CAGR (2026-2035). National reimbursement systems, health technology assessment processes, and a developed biosimilar framework make market access and negotiated net pricing key determinants of therapy uptake.
Germany
Germany generated USD 1.05 billion in 2025 and is forecast to reach USD 1.75 billion by 2035. Its established retinal care infrastructure and benefit-assessment framework can support early access while maintaining pressure on manufacturer net realization.
UK
The UK is projected to generate USD 1.25 billion by 2035 and grow at a 5.2% CAGR (2026-2035). National appraisal and procurement decisions shape which innovative agents can gain meaningful scale through the NHS pathway.
France
France accounted for 3.3% of revenue in 2025 and is projected to generate USD 1.05 billion by 2035. Early-access mechanisms and centralized hospital dispensing can influence the pace at which novel retinal therapies enter routine use.
Italy
Italy is expected to represent 2.2% of revenue by 2035, compared with 2.6% in 2025. Managed-entry approaches and budget controls moderate revenue capture, even as biosimilar availability can improve treatment affordability.
Spain
Spain represented 2.0% of revenue in 2025 and is projected to account for 1.8% by 2035. Decentralized implementation of reimbursement and substitution policies creates local variation in access and procurement behavior.
Netherlands
The Netherlands is projected to generate USD 320 million by 2035 and grow at a 5.9% CAGR (2026-2035). A preference for cost-efficient treatment options constrains average revenue per patient, even as retinal care demand remains clinically important.
Rest of Europe
Rest of Europe accounted for 3.6% of revenue in 2025 and is forecast to grow at a 10.5% CAGR (2026-2035). Expanding injection capacity, updated formularies, and formalization of retinal care pathways support faster development across smaller and emerging national markets.
Asia Pacific Retinal Disorder Treatment Market Analysis
Asia Pacific accounted for 16.0% of retinal disorder treatment market revenue in 2025 and is expected to represent 23.0% by 2035. The region combines a substantial diabetes burden with rapid population aging, while expanding specialist capacity and reimbursement pathways create the conditions for stronger treatment-volume growth.
China
China represented 5.9% of revenue in 2025 and is projected to account for 9.9% by 2035. National reimbursement negotiations, domestic biologic development, and a large addressable patient population make access expansion a defining source of growth.
Japan
Japan is forecast to generate USD 1.2 billion by 2035 and grow at a 7.2% CAGR (2026-2035). Its aging demographic profile and established specialty ophthalmology infrastructure support continuing demand for advanced retinal therapeutics.
India
India accounted for 1.9% of revenue in 2025 and is projected to generate USD 900 million by 2035. Affordability, geographic distribution of retinal specialists, and insurance coverage remain constraints, while lower-cost biosimilars can expand the treated population.
Australia
Australia is projected to generate USD 550 million by 2035 and grow at a 7.0% CAGR (2026-2035). Public reimbursement decisions and metropolitan specialist capacity underpin access to anti-VEGF therapies across established indications.
South Korea
South Korea represented 1.2% of revenue in 2025 and is forecast to expand at an 8.6% CAGR (2026-2035). National insurance coverage and domestic biosimilar capabilities create both competitive pressure and a platform for broader treatment availability.
Rest of APAC
Rest of APAC is projected to account for 4.5% of revenue by 2035 and grow at a 13.5% CAGR (2026-2035). Earlier-stage retinal care markets can grow quickly as private capacity develops and public formularies progressively incorporate modern retinal therapies.
Latin America Retinal Disorder Treatment Market Analysis
Latin America is projected to generate USD 1.82 billion by 2035 and grow at a 9.2% CAGR (2026-2035). Demand is supported by diabetes prevalence and improving urban ophthalmology infrastructure, although public purchasing practices and private insurance access continue to shape product mix.
Brazil
Brazil generated USD 320 million in 2025 and is projected to reach USD 790 million by 2035. Its mixed public-private system creates distinct access routes for branded therapies and cost-managed biologic alternatives.
Mexico
Mexico is forecast to generate USD 440 million by 2035 and expand at a 9.4% CAGR (2026-2035). Growth relies on the extension of specialist care beyond major urban centers and continued development of treatment capacity for diabetic retinal disease.
Argentina
Argentina is projected to generate USD 240 million by 2035 and accounted for 0.5% of revenue in 2025. Economic and import-related constraints can affect access to newer biologics, while established metropolitan specialist centers maintain treatment activity.
Rest of Latin America
Rest of Latin America represented 0.8% of revenue in 2025 and is forecast to grow at an 8.7% CAGR (2026-2035). Expansion in private ophthalmology capacity and gradual formulary development support broader adoption across the cluster.
Middle East & Africa (MEA) Retinal Disorder Treatment Market Analysis
Middle East & Africa (MEA) generated USD 564 million in 2025 and is projected to reach USD 1.09 billion by 2035. The region spans well-funded Gulf markets with sophisticated ophthalmology services and larger populations where specialist retinal care remains limited.
Saudi Arabia
Saudi Arabia accounted for 0.9% of revenue in 2025 and is projected to generate USD 360 million by 2035. Government-funded healthcare and increasing adoption of advanced retinal therapies support demand in a market with a substantial diabetic patient population.
UAE
The UAE is projected to generate USD 260 million by 2035 and grow at an 8.0% CAGR (2026-2035). Concentrated ophthalmology hubs and broad insurance coverage support consistent access to intravitreal treatment.
South Africa
South Africa accounted for 0.5% of revenue in 2025 and is projected to generate USD 170 million by 2035. The private sector remains the main route to advanced retinal care, while public-system capacity constraints limit broader treatment uptake.
Rest of MEA
Rest of MEA is projected to account for 0.8% of revenue by 2035, compared with 1.0% in 2025. Government investment can improve retinal care access in selected markets, but specialist shortages and affordability remain persistent barriers across much of the region.
GMI Analyst View
We expect regional outcomes to diverge according to the maturity of retinal care pathways rather than epidemiology alone. North America remains commercially important because it can adopt innovation early, while Asia Pacific offers the strongest structural expansion potential as diagnosis, reimbursement, and specialist capacity develop together.
Retinal Disorder Treatment Market Share & Competitive Landscape
The retinal disorder treatment market share landscape is concentrated, with the top five companies collectively accounting for approximately 73% of global revenue in 2025. Established anti-VEGF franchises retain substantial influence, but biosimilars, complement inhibition, sustained-release delivery, and gene therapy are widening the basis of competition.
Regeneron Pharmaceuticals held approximately 25% of the market in 2025, supported by the EYLEA franchise and conversion toward EYLEA HD. The company's competitive position depends on balancing differentiated dosing and clinical familiarity against biosimilar substitution in established anti-VEGF indications.
Roche / Genentech held approximately 20% of the market in 2025, led by Vabysmo and supported by a broader ophthalmology platform that includes sustained-release and inherited retinal disease capabilities. Its differentiation rests on reducing treatment burden while sustaining physician confidence in outcomes across major retinal indications.
Bayer AG held approximately 15% of the market in 2025 through the ex-U.S. EYLEA commercial partnership. Its performance remains closely connected to anti-VEGF demand, formulary decisions, and the pace at which biosimilars alter pricing and volume in key international markets.
Novartis maintains a retinal position through Beovu and legacy ranibizumab exposure, with extended-interval treatment positioning offset by the gradual erosion of off-patent franchise value. Apellis and Astellas Pharma / Iveric Bio have created a competitive focal point in geographic atrophy, where payer coverage and real-world adoption will determine the depth of the new treatment category.
AbbVie and REGENXBIO are advancing retinal gene therapy development, while Spark Therapeutics / Roche remains a reference point for inherited retinal disease commercialization. Alimera Sciences, Bausch + Lomb, Santen Pharmaceutical, Adverum Biotechnologies, 4D Molecular Therapeutics, Ocugen, and Outlook Therapeutics contribute across implantable delivery, surgical care, regional ophthalmology, and emerging genetic or ophthalmic biologic platforms. Competitive advantage increasingly depends on evidence generation, manufacturing capability, reimbursement execution, and the ability to fit new modalities into retinal practice workflows.
Recent Industry Developments
Eli Lilly and Company announced the acquisition of Adverum Biotechnologies in October 2025 and completed the transaction in December 2025. The acquisition adds Ixo-vec, an intravitreal gene therapy program for wet AMD, to Lilly's portfolio and signals increased strategic interest in durable retinal treatment approaches for prevalent indications [6]Eli Lilly and Company. "Lilly to Acquire Adverum Biotechnologies." investor.lilly.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →